FDA于2026年6月11日举办以患者为中心的口服仿制药生物等效性挑战研讨会
Advancing Generic Drug Development: Bioequivalence Challenges for Patient-Centric Oral Formulations - 06/11/2026
FDA于2026年6月11日举办以患者为中心的口服仿制药生物等效性挑战研讨会,页面汇集各讲题录音与幻灯片。议题覆盖咀嚼片、口崩片、颗粒/微丸、混悬剂及舌下/颊部制剂,并涉及PBPK建模和儿科制剂开发。会议设两场问答,讲者来自CDER仿制药办公室等。
Webcast | Virtual
Event Title
Advancing Generic Drug Development: Bioequivalence Challenges for Patient-Centric Oral Formulations
- Date:
- June 11, 2026
Visit CDER Small Business and Industry Assistance (SBIA) Homepage
Topics & Presentations | Speakers |
|---|---|
Session 1 | |
Current Landscape of Patient-Centric Formulations in Generic Drug Development | Karen Li, PharmD Pharmacologist Division of Therapeutic Performance II (DTP II) Office of Research and Standards (ORS) Office of Generic Drugs (OGD) | CDER |
Developing Pediatric Formulations: Regulatory Considerations | Vilayat Sayeed, PhD Division Director Division of Product Quality Assessment II Office of Product Quality Assessment I (OPQA I) Office of Pharmaceutical Quality (OPQ) | CDER |
Suitability Petitions: An Avenue for Patient-Centric Formulations | Andrew Fine, PharmD Associate Director for Regulatory Affairs Office of Safety and Clinical Evaluation OGD | CDER |
Extrapolation Using PBPK Modeling to Support the Development of Pediatric Products | Fang Wu, PhD Senior Pharmacologist Division of Quantitative Methods and Modeling ORS | OGD | CDER |
Questions and Answer Session 1 | Moderator Panelists |
Session 2 | |
Bioequivalence Strategies for Chewable Tablets: Regulatory Considerations | Hye Lim Lim, PharmD Visiting Associate DTP II | ORS | OGD | CDER |
Granules and Pellets PSGs | Wen Cheng Yang, MD Senior Staff Fellow DTP II | ORS | OGD | CDER |
Dose Selection Consideration for Pharmacokinetic Bioequivalence Studies of Oral Suspension Products | Duyen Nguyen, PharmD Staff Fellow DTP II | ORS | OGD | CDER |
Scientific and Regulatory Considerations for Sublingual Products | Wei-Jhe Sun, PhD Senior Staff Fellow DTP II | ORS | OGD | CDER |
Bioequivalence Strategies for Orally Disintegrating Tablets: Regulatory Considerations | Heather Boyce, PhD Lead Pharmacokineticist DTP II | ORS | OGD | CDER |
In Vitro Feeding Tube Studies: Scientific and Regulatory Perspectives | Geng Tian, PhD Shamema Nasrin, PhD |
Questions and Answer Session 2 | Moderator Panelists |
Closing Remarks | Myong-Jin Kim, PharmD Division Director DTP II | ORS | OGD | CDER |
About this Event (Hosted by CDER SBIA)
The field of patient-specialized oral drug formulations continues to evolve, presenting unique bioequivalence (BE) challenges that require innovative regulatory approaches. This workshop is designed to facilitate discussions about the latest advancements and regulatory considerations in the evolving field of patient-centric (including pediatric) generic oral products, addressing product development and regulatory assessment challenges for these important medicines.
Attendees will gain valuable insights into the intricacies of developing generic versions of specialized oral formulations across diverse areas. The scope of discussions will include chewable tablets, orally disintegrating tablets, pellet/granule formulations, suspension products, and sublingual/buccal formulations. This workshop will also address challenges for the development and assessment of generic pediatric-specific formulations designed to meet the unique needs of patient populations with swallowability challenges.
Through a series of expert-led presentations and Q&A sessions, participants will have the opportunity to hear from and pose questions to experts from FDA, to help deepen their understanding of current best practices, challenges and opportunities, regulatory expectations, and emerging trends. Specifically, the workshop will cover critical areas such as regulatory strategies for patient-centric formulations, formulation-specific development issues, regulatory strategies for pediatric formulations, and innovative BE approaches including physiologically based pharmacokinetic (PBPK) modeling to support generic pediatric product development. These topics reflect some of the most challenging issues facing patient-centric oral generic drug development, and the workshop will facilitate a discussion of the scientific and regulatory innovations being deployed to overcome these challenges.
Don't miss this unique opportunity to learn how to improve your generic drug development!
Intended Audience
Scientists, researchers, current and prospective generic drug applicants, and regulatory affairs professionals who work on or have an interest in the development of oral generic drugs.
Topics Covered
- Common regulatory challenges of patient-centric oral formulations
- Up-to-date formulation-specific regulatory strategies and best practices to support the product development and BE evaluation (including feeding tube studies and BE study dose selection) of various patient-centric oral formulations, including chewable tablets, pellets/granules, sublingual/buccal products, orally disintegrating tablets, and suspensions.
- Known issues and practical strategies for the development of generic oral pediatric formulations
Learning Objectives
- Stay up to date with the latest advancements in science, research, FDA guidance recommendations, and regulatory perspectives related to relevant oral generic drug products
- Recognize and explain how the FDA's GDUFA-funded research can be leveraged to support and inform generic drug development
- Learn how to utilize various strategies and methodologies to facilitate efficient generic drug development
Resources
来源:FDA 官方药品与生物制品信息 · fda.gov